The global Iliac stent market size is expected to reach USD 1,708.54 Million by 2032, exhibiting the CAGR of 5.6% during the forecast period.
The iliac stent market is a pivotal segment within the vascular and endovascular devices industry. With advancements in medical technology and increasing prevalence of peripheral artery diseases (PAD), the demand for iliac stents has grown significantly. This article provides a comprehensive overview of the iliac stent market, analyzing its growth drivers, key trends, research scope, and future outlook.
Market Overview
Iliac stents are medical devices used to treat blockages or narrowing in the iliac arteries, which supply blood to the pelvic region and lower limbs. They play a crucial role in revascularization procedures by restoring proper blood flow and minimizing complications such as limb ischemia.
𝐆𝐞𝐭 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐚𝐠𝐞𝐬 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.polarismarketresearch.com/industry-analysis/iliac-stent-market/request-for-sample
Market Growth Drivers
3.1 Rising Prevalence of PAD
Peripheral artery disease is a leading cause of morbidity worldwide. The growing number of patients with PAD necessitates innovative and effective treatment options, thereby driving the demand for iliac stents.
3.2 Technological Advancements
The introduction of advanced stent designs, such as bioresorbable stents and hybrid stents, has enhanced patient outcomes and reduced procedure-related complications, boosting market growth.
3.3 Increasing Geriatric Population
An aging global population is at higher risk of vascular disorders, further fueling the need for effective vascular interventions such as iliac stenting.
Key Players:
Some of the major players operating in the global market include:
- Abbott
- BD
- Biotronik SE & Co KG
- Boston Scientific Corporation
- Cook
- Getinge AB
- iVascular
- Medtronic
- Terumo Corporation
- L. Gore & Associates, Inc.
Key Trends in the Iliac Stent Market
4.1 Preference for Minimally Invasive Procedures
The shift towards minimally invasive procedures is a key trend driving the adoption of iliac stents, as these techniques offer reduced recovery time and lower risk of complications.
4.2 Growing Use of Drug-Eluting Stents
Drug-eluting stents have gained popularity due to their ability to reduce restenosis rates, providing a long-term solution for patients with arterial diseases.
4.3 Expansion in Emerging Markets
Emerging economies, particularly in Asia-Pacific and Latin America, are witnessing increased investments in healthcare infrastructure, creating opportunities for market expansion.
Research Scope in the Iliac Stent Market
5.1 Clinical Studies and Trials
Continued research in clinical efficacy and safety of iliac stents is vital for driving innovation and regulatory approvals.
5.2 Material and Design Optimization
Exploration of new materials and stent designs to improve biocompatibility and durability remains a key focus area for researchers.
5.3 Integration of AI and Imaging Technology
Advancements in imaging and artificial intelligence are enabling precise stent placement and personalized treatment approaches.
Future Outlook
The future of the iliac stent market looks promising, with consistent innovation and increased awareness about vascular health. Key developments expected to shape the market include:
- Enhanced regulatory frameworks facilitating faster approvals for innovative products.
- Expansion of telemedicine and remote monitoring technologies complementing stenting procedures.
- Collaborative efforts between key players to address unmet clinical needs.
Recent Developments:
March 2024:
Getinge and Cook Medical announced a commercial distribution agreement for the iCast covered stent in the United States. Recently approved by the FDA, this stent is designed for treating symptomatic iliac arterial occlusive disease. Under the agreement, Cook Medical will handle sales and distribution of the device in the U.S. market.
February 2024:
Gore introduced a lower-profile version of its FDA-approved Viabahn VBX stent graft to the U.S. market. This updated device features an improved delivery system while retaining its original stent design, enhancing ease of use and minimizing access site complications for physicians treating complex iliac artery disease. The new version maintains the trusted performance of its predecessor while improving accessibility and procedural efficiency.